nucleosid
analog
histor
use
anticanc
chemotherapi
inhibit
cellular
dnarna
polymeras
recent
nucleosid
analog
expand
therapeut
applic
use
develop
antivir
drug
wide
rang
seriou
lifethreaten
virus
nucleosid
analog
drug
target
specif
viral
polymeras
acyclovir
herpesvirus
zidovudin
human
immunodefici
viru
hiv
sofosbuvir
hepat
c
viru
hcv
success
clinic
trial
current
use
treatment
virusinfect
patient
anoth
class
nucleosid
analog
drug
ribavirin
broadlyact
variou
virus
use
conjunct
importantli
extens
studi
antivir
action
ribavirin
establish
underli
molecular
framework
nucleosid
analog
primari
mechan
explain
antivir
effect
nucleosid
analog
base
direct
action
viral
polymer
nucleosid
analog
transport
cell
phosphoryl
consecut
action
viral
cellular
kinas
eventu
gener
nucleotid
triphosph
matur
nucleotid
analog
similar
physiolog
nucleotid
directli
incorpor
grow
viral
genom
polymer
result
termin
chain
reaction
accumul
mutat
figur
altern
nucleotid
analog
bind
nucleotidebind
region
viral
polymeras
block
entri
incom
natur
nucleotid
mechan
base
modul
cellular
nucleo
ide
synthesi
accumul
report
nucleosid
analog
act
antivir
agent
interf
host
nucleo
ide
synthesi
pathway
target
metabol
enzym
nucleosid
analog
block
natur
flow
nucleo
ide
synthesi
consequ
caus
deplet
imbal
ntp
pool
viral
replic
highli
depend
avail
host
nucleotid
nucleotidedefect
condit
decreas
effici
viral
replic
recent
propos
mechan
base
observ
nucleosid
analog
activ
innat
immun
especi
involv
upregul
interferonstimul
gene
isg
importantli
phenomenon
usual
mediat
inhibit
nucleotid
synthesi
suggest
potenti
crosstalk
nucleotid
biosynthesi
innat
immun
howev
precis
mechan
crosstalk
remain
elucid
increas
number
nucleosid
analog
antivir
activ
toward
wide
rang
virus
wellsummar
previou
report
present
review
focu
gemcitabin
nucleosid
analog
clinic
relev
whose
broadspectrum
antivir
activ
recent
report
mani
group
includ
group
importantli
summar
inhibitor
purinepyrimidin
biosynthesi
pathway
induc
innat
immun
propos
possibl
mechan
action
inhibitor
gemcitabin
cytidin
analog
clinic
use
treatment
variou
cancer
howev
recent
year
antivir
activ
gemcitabin
also
report
broad
rang
rna
virus
includ
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
zika
viru
zikv
hcv
polioviru
pv
influenza
viru
iav
hiv
enterovirus
ev
antivir
activ
gemcitabin
abovement
virus
summar
tabl
merscov
sarscov
belong
famili
coronavirida
caus
agent
sever
viral
respiratori
ill
human
effici
select
appropri
antivir
drug
candid
dyall
et
al
screen
fdaapprov
drug
virusinfect
vero
cell
identifi
gemcitabin
one
drug
antivir
activ
merscov
sarscov
respect
recent
gemcitabin
shown
effect
suppress
zikv
infect
replic
human
retin
pigment
epithelium
rpe
cell
particularli
noncytotox
concentr
vs
zikv
member
flavivirida
famili
infect
pregnant
women
caus
congenit
abnorm
microcephali
infant
attract
increas
public
attent
well
extens
research
develop
possibl
treatment
effect
antivir
activ
gemcitabin
also
found
replic
hcv
cell
infect
hiv
cell
estim
nm
nm
respect
lower
concentr
use
cancer
therapi
case
hiv
combin
gemcitabin
decitabin
anoth
nucleosid
analog
clinic
use
cancer
therapi
synergist
reduc
hiv
infect
increas
viral
mutat
frequenc
follow
studi
clouser
et
al
report
antivir
effect
gemcitabin
hivrel
retroviru
murin
leukemia
viru
mulv
vitro
nm
even
murin
aid
model
signific
antivir
effect
gemcitabin
iav
also
report
rpe
cell
denisova
et
al
also
test
whether
gemcitabin
antivir
effect
sever
virus
differ
famili
found
strong
inhibitori
effect
sindbi
viru
herp
simplex
log
reduct
viru
titer
rel
weak
effect
semliki
forest
viru
human
echoviru
minim
effect
bunyamwera
viru
measl
viru
mev
vaccinia
viru
antivir
effect
gemcitabin
ev
initi
perform
coxsackieviru
found
screen
fdaapprov
drug
repliconharbor
vero
cell
group
broadspectrum
antivir
activ
ev
identifi
observ
similar
inhibitori
effect
enteroviru
human
rhinovirus
hrv
respect
case
hrv
antivir
effect
gemcitabin
confirm
virusinfect
mous
model
studi
intranas
administr
gemcitabin
significantli
lower
pulmonari
viral
load
inflamm
decreas
proinflammatori
cytokin
includ
number
lung
infiltr
lymphocyt
recent
zhang
et
al
also
identifi
gemcitabin
best
antipv
inhibitor
screen
fdaapprov
drug
pv
repliconharbor
hela
cell
previous
mention
accumul
evid
definit
demonstr
gemcitabin
effect
broadspectrum
inhibitor
rna
virus
therapeut
potenti
treatment
variou
virusassoci
diseas
moreov
possibl
gemcitabin
effect
untest
rna
virus
gemcitabin
deoxycytidin
analog
interfer
dna
well
rna
synthesi
dna
virus
may
except
consist
possibl
report
infect
repres
dna
viru
classifi
herpesvirida
famili
strongli
affect
gemcitabin
abovement
virus
best
limit
prophylact
therapeut
drug
possibl
treatment
especi
true
newli
emerg
reemerg
virus
involv
seriou
ill
merscov
sarscov
zikv
major
threat
public
health
urgent
need
effect
treatment
earli
stage
infect
regard
repurpos
gemcitabin
treatment
patient
infect
deadli
virus
realist
approach
importantli
noteworthi
zikv
strongli
affect
gemcitabin
low
nanomolar
lower
use
cancer
therapi
even
virus
rel
high
option
treat
patient
combin
gemcitabin
antivir
agent
manner
effect
antivir
treatment
may
achiev
synergist
action
two
antivir
much
lower
dose
drug
minim
deleteri
side
effect
use
clinic
exampl
synergist
antivir
effect
gemcitabin
combin
ribavirin
antivir
drug
current
use
rna
virus
report
ev
previous
mention
combin
gemcitabin
decitabin
synergist
suppress
hiv
infect
vitro
vivo
howev
actual
use
gemcitabin
virusinfect
patient
necessit
prior
vivo
anim
studi
clinic
trial
even
though
antivir
data
origin
vitro
studi
two
recent
studi
report
antivir
effect
gemcitabin
murin
model
extens
analys
gemcitabin
anim
model
near
futur
acceler
therapeut
applic
clinic
trial
studi
regard
antivir
activ
gemcitabin
lack
experiment
evid
mode
action
howev
group
recent
report
gemcitabin
antiev
effect
target
salvag
pathway
pyrimidin
biosynthesi
moreov
gemcitabin
strongli
induc
express
sever
isg
includ
major
effector
innat
immun
defend
host
viru
infect
result
consist
previou
report
gemcitabin
stimul
product
iavinfect
rpe
cell
importantli
activ
isg
wellcorrel
inhibit
pyrimidin
biosynthesi
suggest
link
pyrimidin
biosynthesi
innat
immun
similar
phenomena
term
isg
activ
previous
report
compound
sever
purin
pyrimidin
biosynthesi
inhibitor
antivir
activ
summar
tabl
regard
purin
biosynthesi
inhibitor
ribavirin
mycophenol
acid
mpa
inhibitor
imp
dehydrogenas
impdh
key
enzym
purin
biosynthesi
pathway
inhibitor
success
use
clinic
antivir
immunosuppress
agent
decad
antivir
activ
virus
hcv
hepat
e
viru
hev
merscov
dengu
viru
yellow
fever
hepat
b
viru
west
nile
viru
wnv
chikungunya
viru
chikv
iav
majorli
inhibit
purin
biosynthesi
pathway
antivir
activ
hcv
hev
shown
involv
stimul
isg
antivir
activ
ribavirin
hcv
ribavirin
specif
induc
express
mrna
known
import
antihcv
immun
respons
isg
activ
occur
undefin
mechan
differ
classic
ifn
signal
intracellular
dsrna
sens
pathway
tolllik
receptor
nuclear
factor
b
pathway
importantli
ribavirininduc
isg
activ
antivir
activ
suppress
use
supplement
guanosin
natur
analog
ribavirin
suggest
impdh
inhibitionmedi
isg
activ
altern
innat
immun
pathway
like
ribavirin
mpa
remark
induc
express
sever
isg
includ
mrna
hevinfect
cell
induct
isg
least
partial
abrog
use
supplement
guanosin
mechanist
induct
isg
mpa
independ
classic
jakstat
system
similar
observ
ribavirin
similar
result
obtain
sever
inhibitor
variou
affin
customdesign
synthes
shown
tabl
pyrimidin
biosynthesi
inhibitor
target
dihydroorot
dehydrogenas
dhodh
essenti
enzym
de
novo
pyrimidin
synthesi
lucashourani
et
al
identifi
interferonsensit
respons
element
isr
stimul
compound
highthroughput
screen
analys
suggest
dhodh
inhibitor
strong
antivir
activ
variou
virus
includ
mev
chikv
wnv
enhanc
express
sever
isg
almost
complet
suppress
addit
supplement
uridin
indic
dhodh
inhibitionmedi
isg
activ
moreov
antivir
activ
isg
activ
requir
interferon
regulatori
factor
transcript
factor
master
regul
antivir
gene
express
consist
observ
antihcv
activ
mpa
partial
mediat
studi
similar
result
shown
brequinar
anoth
wellknown
dhodh
inhibitor
also
antivir
compound
inhibit
pyrimidin
biosynthesi
pathway
probabl
via
target
dhodh
induc
express
isg
howev
whether
isg
activ
mediat
pyrimidin
biosynthesi
inhibit
remain
determin
mechan
nucleotid
synthesi
inhibitorinduc
isg
activ
still
present
unclear
nevertheless
accumul
evid
show
nucleotid
synthesi
inhibitorinduc
isg
activ
independ
classic
jakstatmedi
ifn
signal
first
wang
et
al
clearli
show
isg
activ
antihev
activ
induc
mpa
brequinar
mediat
jak
second
induct
ribavirin
affect
knockdown
strongli
affect
condit
third
recent
studi
gemcitabin
confirm
ifn
signalindepend
isg
activ
parallel
studi
compar
effect
gemcitabin
studi
phosphoryl
dramat
trigger
occur
treat
gemcitabin
moreov
upregul
mrna
induc
gemcitabin
affect
knockdown
contrari
result
upregul
mrna
significantli
suppress
condit
consist
observ
report
isg
induc
absenc
activ
despit
limit
data
specul
scenario
isg
activ
independ
jakstatmedi
ifn
signal
purin
pyrimidin
biosynthesi
inhibitor
could
interfer
metabol
pathway
target
key
enzym
impdh
dhodh
lead
deplet
imbal
ntp
pool
inactiv
metabol
enzym
consequ
alter
nucleo
ide
pool
might
trigger
signal
ultim
deliv
certain
cisact
element
promot
subset
isg
possibl
relay
kinas
transcript
factor
base
previous
mention
report
signal
less
like
depend
ifnstimul
gene
factor
least
gemcitabin
major
transcript
complex
ifninduc
jakstat
pathway
also
consid
thoma
et
al
exclud
involv
intracellular
doublestrand
rna
sens
pathway
tolllik
receptor
nuclear
factor
pathway
well
classic
ifn
signal
activ
isg
induc
ribavirin
despit
consensu
isg
activ
purinepyrimidin
biosynthesi
inhibitor
seem
induc
distinct
set
isg
least
differ
pattern
target
enzym
pathway
purin
pyrimidin
synthesi
step
earlyl
de
novosalvag
produc
differ
level
intermedi
nucleo
ide
consequ
result
divers
outcom
isg
activ
might
one
signal
pathway
involv
synergist
antivir
activ
gemcitabin
ribavirin
observ
studi
might
explain
possibl
exist
two
separ
signal
pathway
mediat
inhibit
nucleotid
synthesi
toward
isg
activ
systemat
analys
signal
kinas
irf
stat
use
sirna
knockdown
andor
pharmacolog
inhibit
metabol
analys
correspond
intermedi
nucleo
ide
therefor
clarifi
underli
molecular
mechan
isg
activ
purinepyrimidin
biosynthesi
inhibitor
newli
emerg
reemerg
virus
sarscov
merscov
zikv
becom
major
threat
public
health
need
broadspectrum
antivir
drug
increas
regard
nucleosid
analog
directli
target
viral
rnadepend
rna
polymeras
present
high
barrier
develop
resist
virus
consid
advantag
moreov
recent
discoveri
new
antivir
mode
nucleosid
analog
act
innat
immun
strengthen
molecular
basi
therapeut
applic
broadspectrum
antivir
drug
nucleosid
analog
probabl
induc
differ
subset
isg
least
differ
pattern
lead
variou
combin
isg
result
antivir
outcom
moreov
accord
schoggin
et
al
differ
virus
affect
distinct
subset
isg
isg
hpse
mda
act
broadli
variou
virus
thu
systemat
analys
subset
isg
induc
antivir
nucleosid
analog
requir
identif
better
antivir
drug
use
broadli
specif
given
clinic
side
effect
ifn
treatment
nucleotid
analog
differ
ifn
activ
subset
isg
need
consid
altern
nevertheless
nucleosid
analog
interf
host
nucleotid
synthesi
pathway
suggest
possibl
side
effect
clinic
applic
care
evalu
clinic
safeti
requir
applic
urgent
measur
patient
infect
deadli
virus
would
worth
primarili
consid
